Blood test may guide treatment for relapsed kidney disease
NCT ID NCT05428605
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed lab study took blood samples from 20 adults with relapsed membranous nephropathy, a kidney condition. Researchers tested different immune-modulating drugs on the blood cells to see how they affect the balance of Th17 and Treg immune cells. The goal is to find which drug might work best for each patient based on their immune profile, but this is early research and not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors choose the best immune drug for patients with relapsed membranous nephropathy based on their immune profile.
- What could go wrong
- This is a very early lab study using blood samples, not a treatment trial. Results may not translate to real patient outcomes, and the small sample size limits generalizability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAMEMBRANOUS GLOMERULOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Hospitalier Universitaire de Nice
Nice, 06200, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.